Premium
Regulation of DUI45 human prostate cancer cell proliferation by insulin‐like growth factors and its interaction with the epidermal growth factor autocrine loop
Author(s) -
Connolly Jeanne M.,
Rose David P.
Publication year - 1994
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990240402
Subject(s) - autocrine signalling , du145 , paracrine signalling , epidermal growth factor , endocrinology , growth factor , medicine , insulin like growth factor , biology , growth factor receptor inhibitor , epidermal growth factor receptor , secretion , receptor , cancer cell , cancer , lncap
The DU145 human prostate cancer cell line was shown to possess type I insulin‐like growth factor receptors (IGFR). The addition of either IGF‐I or IGF‐II, but not insulin, to serum‐free culture medium increases the rate of thymidine incorporation by the cells, a response which is suppressed by specific blockade of the previously described epidermal growth factor (EGF) autocrine growth regulatory loop. The DU145 cells secrete into conditional medium a specific IGF‐binding protein (IGFBP) precipitated by an antibody to IGFBP‐1, and whose secretion is also suppressed by interruption of the EGF autocrine loop. This IGFBP may modulate the bioactivity of IGFs arising from endocrine or paracrine sources in vivo. After removal of IGFBPs from the conditioned medium, no secretion of either IGF‐I or IGF‐II by this prostate cancer cell line is detected by radioimmunoassay and radioreceptor assay, respectively. © 1994 Wiley‐Liss, Inc.